C-Type Natriuretic Peptide (CNP) (1-22), human

C-Type Natriuretic Peptide (CNP) (1-22), human, a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor^[1][2][3]. IC50 & Target:NPR-B^[1] In Vitro: C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) (0.01, 0.1, 1, 10, 100, 1000 nM) increases cGMP production in CHO cells expressing human NPR-B in a concentration-dependent manner^[1]. In Vivo: PK parameters of CNP immunoreactivity after a single intravenous administration of C-Type Natriuretic Peptide (CNP) (1-22), human^[1]:

Dose (nM/kg)	AUC0-∞ (pM·min/mL)	MRT0-∞ (min)	T1/2 (min)	CLtot (mL/min/kg)	Vdss (mL/kg)
20	320±54	1.02±0.18	1.42±0.45	63.9±11.9	64.2±5.1

PK parameters of CNP immunoreactivity after a single subcutaneous administration of C-Type Natriuretic Peptide (CNP) (1-22), human^[1]:

Dose (nM/kg)	Cmax (pM/mL)	Tmax (min)	AUC0-∞ (pM·min/mL)	MRT0-∞ (min)	T1/2 (min)	BA (%)
50	9.02±3.74	5.0±0.0	152±73	13.9±3.4	10.0±5.0	19±9

Each value represents the mean±SD of 3 rats. MRT=mean residence time, CL_tot=total clearance, T_1/2=half-life period, BA=bioavailability.
C-Type Natriuretic Peptide (CNP) (1-22) ( i.c.v.) in a dose of 2 nM induces an increase in the severity of picrotoxin-kindled convulsions 24 and 48 hrs after application of the peptide^[3].